RA

Pluton Biosciences Raises $16.5M Series A led by Illumina Ventures and RA Capital to discover and deploy microbes that will fight climate change

Retrieved on: 
Wednesday, May 24, 2023

"The funding will accelerate the development of Pluton's flagship product, the Microbial Cover Crop™, through field trials and towards commercial partnerships," remarked Elizabeth Gallegos, CEO of Pluton.

Key Points: 
  • "The funding will accelerate the development of Pluton's flagship product, the Microbial Cover Crop™, through field trials and towards commercial partnerships," remarked Elizabeth Gallegos, CEO of Pluton.
  • Pluton's Micromining™ approach, combining genomics with rigorous data science, can unlock the potential of soil microbes for more sustainable agriculture and beyond."
  • We are proud to support Pluton in their work to improve nature's toolkit and revolutionize agriculture."
  • This product will complement many other innovations growers can use to improve their farms' profitability while helping the planet."

AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ® (upadacitinib) Across Multiple Rheumatic Diseases at the EULAR 2023 Congress

Retrieved on: 
Wednesday, May 24, 2023

NORTH CHICAGO, Ill., May 24, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that researchers will present new, long-term data supporting the efficacy and safety profile of RINVOQ® (upadacitinib) from the SELECT-COMPARE, SELECT-PsA 1 and SELECT-AXIS 2 studies at the European Congress of Rheumatology, EULAR 2023, taking place from 31 May – 3 June in Milan.

Key Points: 
  • "These new results from the SELECT trial programs continue to strengthen the breadth of evidence available for RINVOQ's efficacy and safety profile in several rheumatic diseases," said Mudra Kapoor, vice president, global medical affairs, immunology, AbbVie.
  • "Our investment in long-term data is an essential part of AbbVie's ongoing commitment to ensure we are supporting patients living with immune-mediated diseases."
  • "These efficacy and safety data provide additional information to help healthcare providers make important treatment choices with their patients and highlight the ability to maintain disease control with long-term treatment."
  • AbbVie reported initial results at week 14 from the SELECT-AXIS 2 AS bDMARD-IR study during the EULAR 2022 Congress.

FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients

Retrieved on: 
Monday, May 22, 2023

AUSTIN, Texas, May 22, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today reports that the FDA’s Division of Rheumatology has authorized the Company to initiate a Phase II clinical study to test Natrunix™ as a treatment for Rheumatoid Arthritis.

Key Points: 
  • AUSTIN, Texas, May 22, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today reports that the FDA’s Division of Rheumatology has authorized the Company to initiate a Phase II clinical study to test Natrunix™ as a treatment for Rheumatoid Arthritis.
  • The randomized, double-blind, placebo-controlled, trial will examine the effectiveness of Natrunix to treat rheumatoid arthritis compared to placebo in subjects already receiving stable but inadequate treatment with methotrexate (MTX).
  • A total of 210 patients will be randomly distributed in equal numbers into three groups: including two different Natrunix dosages and a placebo group.
  • The Phase II study in rheumatoid arthritis is the culmination of XBiotech efforts to pioneer therapies derived from natural human immunity.

The Coalition for PSP Modernization Praises Graves & Davids’ Introduction of the Motor Carrier Safety Screening Modernization Act to Strengthen Roadway Safety and Improve Driver Retention

Retrieved on: 
Wednesday, May 17, 2023

3356 ) that expands voluntary access to the Federal Motor Carrier Safety Administration (FMCSA) Pre-Employment Screening Program (PSP) to allow the review of these important driver safety records on an ongoing basis, rather than only when a motor carrier is in the hiring process.

Key Points: 
  • 3356 ) that expands voluntary access to the Federal Motor Carrier Safety Administration (FMCSA) Pre-Employment Screening Program (PSP) to allow the review of these important driver safety records on an ongoing basis, rather than only when a motor carrier is in the hiring process.
  • Unfortunately, federal statute limits motor carrier access to PSP to the pre-hire review of a driver’s safety record.
  • The Motor Carrier Safety Screening Modernization Act makes minor changes to existing statutory language to also allow voluntary access to PSP records for current employees.
  • Carriers will also be able to build periodic PSP queries into their driver safety, coaching, and incentive programs - leading to stronger driver retention.

DxVx appoints Yong Gu Lee as new CEO and Kevin Kwon as the new president

Retrieved on: 
Tuesday, May 16, 2023

SEOUL, South Korea, May 16, 2023 /PRNewswire/ -- DxVx announced on the 16th, the board of directors appointed Yong Gu Lee as the new CEO and Kevin Kwon, the former head of global business division at Hanmi Pharm.Co.,Ltd., as the new president. Drawing on the expertise of sales veterans who have more than 30 years of experience, the company plans to actively reorganize the global sales networks, launch new products and further enhance its capabilities to get global approvals for new drugs.

Key Points: 
  • SEOUL, South Korea, May 16, 2023 /PRNewswire/ -- DxVx announced on the 16th, the board of directors appointed Yong Gu Lee as the new CEO and Kevin Kwon, the former head of global business division at Hanmi Pharm.Co.,Ltd., as the new president.
  • The new CEO, Yong Gu Lee, graduated from Hanyang University.
  • Co., Ltd., managing director of the healthcare business division at Beijing Medi'Care Co., Ltd and vice president of the COREE Group.
  • New president Kevin Kwon will be appointed as a board director from a shareholders' meeting.

Orchard Therapeutics Reports First Quarter 2023 Financial Results and Announces Initiation of Rolling Submission for Biologics License Application of OTL-200 for Metachromatic Leukodystrophy to U.S. FDA

Retrieved on: 
Monday, May 15, 2023

BOSTON and LONDON, May 15, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced various business accomplishments along with its financial results for the quarter ended March 31, 2023.

Key Points: 
  • OTL-200 is approved as Libmeldy® (atidarsagene autotemcel) by the European Commission (EC) and Medicines and Healthcare products Regulatory Agency (MHRA).
  • The company has secured reimbursement agreements for Libmeldy in three new markets so far in 2023.
  • Orchard Therapeutics has outlined the following key milestones expected for 2023:
    Libmeldy: Establish qualified treatment centers in Sweden, Spain and Saudi Arabia.
  • The company had approximately 184.3 million ordinary shares, equivalent to 18.4 million American Depositary Shares, outstanding as of March 31, 2023.

Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Monday, May 8, 2023

WAYNE, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2023 and provided a corporate update.

Key Points: 
  • WAYNE, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2023 and provided a corporate update.
  • Based on the continued positive enrollment momentum, Aclaris is narrowing its timing guidance for topline data to the fourth quarter of 2023.
  • As a result, Aclaris currently projects topline data in the second half of 2023, rather than mid-year 2023.
  • Net loss was $28.2 million for the first quarter of 2023 compared to $18.8 million for the first quarter of 2022.

Companies Seek to Promote Diversity with AI-Powered Recruitment

Retrieved on: 
Friday, May 5, 2023

NEW YORK, May 5, 2023 /PRNewswire/ -- Artificial intelligence (AI) is changing the way we live and work in unprecedented ways. Recent developments in AI technologies are making it possible for machines to learn and interact with the world. Furthermore, as the technology continues to evolve, it has the potential to transform various aspects of our lives, from healthcare and education to finance and transportation. Currently, AI can perform a wide range of tasks as algorithms can now detect patterns in large datasets, recognize speech and images, and understand natural language. AI systems can also perform complex assignments like playing games, composing music, and generating realistic images and videos. Recent advancements in AI have made it possible for machines to learn from experience and improve their performance over time. This is known as machine learning, and it is a key component of many AI applications today. Machine learning algorithms can be trained on large datasets to recognize patterns and make predictions about future events. This has led to breakthroughs in areas like natural language processing, image recognition, and predictive analytics. Professional Diversity Network, Inc. (NASDAQ: IPDN), SoundHound AI, Inc. (NASDAQ: SOUN), Guardforce AI Co., Limited (NASDAQ: GFAI), IonQ, Inc. (NYSE: IONQ), Palantir Technologies Inc. (NYSE: PLTR)

Key Points: 
  • In addition, AI also has the potential to be a powerful tool for promoting diversity and inclusion in the workplace.
  • AI can help companies to identify and eliminate bias in their recruitment and hiring processes, which can help to diversify the workforce.
  • RemoteMore has been working on an artificial intelligence (AI) solution that improves the matchmaking between companies and developers.
  • Palantir was among the select companies that Forrester invited to participate in "The Forrester Wave™: AI/ML Platforms, Q3 2022" report.

Companies Seek to Promote Diversity with AI-Powered Recruitment

Retrieved on: 
Friday, May 5, 2023

NEW YORK, May 5, 2023 /PRNewswire/ -- Artificial intelligence (AI) is changing the way we live and work in unprecedented ways. Recent developments in AI technologies are making it possible for machines to learn and interact with the world. Furthermore, as the technology continues to evolve, it has the potential to transform various aspects of our lives, from healthcare and education to finance and transportation. Currently, AI can perform a wide range of tasks as algorithms can now detect patterns in large datasets, recognize speech and images, and understand natural language. AI systems can also perform complex assignments like playing games, composing music, and generating realistic images and videos. Recent advancements in AI have made it possible for machines to learn from experience and improve their performance over time. This is known as machine learning, and it is a key component of many AI applications today. Machine learning algorithms can be trained on large datasets to recognize patterns and make predictions about future events. This has led to breakthroughs in areas like natural language processing, image recognition, and predictive analytics. Professional Diversity Network, Inc. (NASDAQ: IPDN), SoundHound AI, Inc. (NASDAQ: SOUN), Guardforce AI Co., Limited (NASDAQ: GFAI), IonQ, Inc. (NYSE: IONQ), Palantir Technologies Inc. (NYSE: PLTR)

Key Points: 
  • In addition, AI also has the potential to be a powerful tool for promoting diversity and inclusion in the workplace.
  • AI can help companies to identify and eliminate bias in their recruitment and hiring processes, which can help to diversify the workforce.
  • RemoteMore has been working on an artificial intelligence (AI) solution that improves the matchmaking between companies and developers.
  • Palantir was among the select companies that Forrester invited to participate in "The Forrester Wave™: AI/ML Platforms, Q3 2022" report.

Galapagos announces first quarter 2023 financial results

Retrieved on: 
Thursday, May 4, 2023

Progress with immunology and oncology pipeline:

Key Points: 
  • Progress with immunology and oncology pipeline:
    Clinical sites opened to start patient recruitment in Phase 2 GALARISSO study with TYK2 inhibitor product candidate, GLPG3667, in dermatomyositis (DM)
    Further expanding CAR-T point-of-care network in Europe, with IND filing in the US expected before year-end
    First quarter 2023 financial highlights:
    Webcast presentation tomorrow, 5 May 2023, at 14:00 CET / 8:00 am ET, www.glpg.com
    Mechelen, Belgium; 4 May 2023, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced its first quarter 2023 financial results, a year-to-date business update and its outlook for the remainder of 2023.
  • Within our pipeline, we presented encouraging initial Phase 1/2 results with GLPG5201, our CD19 CAR-T candidate in chronic lymphocytic leukemia.
  • In the first quarter of this year, Jyseleca® achieved €26.7 million in net sales in rheumatoid arthritis (RA) and ulcerative colitis (UC).
  • We continue to gain further insights into the market dynamics for the JAK class and we intend to revisit our 2023 net sales guidance at the next financial update in August.